3,5-dimethyl-4-nitro-1-oxidopyridin-1-ium

We are 3,5-dimethyl-4-nitro-1-oxidopyridin-1-ium CAS:14248-66-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 3,5-dimethyl-4-nitro-1-oxidopyridin-1-ium
CAS.NO: 14248-66-9
Synonyms:
3,5-dimethyl-4-nitropyridine oxide
3,5-Dimethyl-4-nitropyridine 1-oxide
3,5-Dimethyl-4-nitropyridine-N-Oxide
4-nitro-3,5-dimethylpyridine N-oxide

Molecular Formula: C7H8N2O3
Molecular Weight:168.15000

Physical and Chemical Properties:
Density: 1.3 g/cm3
Boiling point:377.2ºC at 760 mmHg
Melting point:174-180 (°C)
Flash point: 181.9ºC
Refractive index: 1.573

Specification:
Appearance:Bright yellow crystalline powder
Purity:≥98%
LOD: NMT 1.0%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Pantoprazole CAS:102625-70-7
Intermediates of Omeprazole magnesium CAS:95382-33-5
Intermediates of Omeprazole CAS:73590-58-6
Intermediates of Rebeprazole CAS:117976-89-3
Intermediates of Rebeprazole sodium CAS:117976-90-6
Intermediates of Omeprazole sodium CAS:95510-70-6

3,5-dimethyl-4-nitro-1-oxidopyridin-1-ium


Related News: In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.28924-21-2 Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.2-Bromo-6-nitrophenol CAS:13073-25-1 According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.L-Serine According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.

Related Products
Product Name
2-Bromotriphenylene View Details
5-Bromo-2,3-difluorophenol View Details
p-Bromo Aniline View Details
4-Bromo-2-fluorotoluene manufacturer N-Acetyl-N-(4-chloro-2-nitrophenyl)acetamide manufacturer ancitabine hydrochloride manufacturer 4-(Difluoromethoxy)benzenesulfonamide manufacturer CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID METHYL ESTER manufacturer